Biostem Tech
Stock
Stock
ISIN: US0906842002
Ticker: BSEM
US0906842002
BSEM
Price
Price
CHART BY
Frequently asked questions
What is Biostem Tech's market capitalization?
The market capitalization of Biostem Tech is $235.93M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Biostem Tech's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Biostem Tech is 22.65. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Biostem Tech?
Biostem Tech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.638. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Biostem Tech's stock?
Currently, 0 analysts cover Biostem Tech's stock, with a consensus target price of $32.50. Analyst ratings provide insights into the stock's expected performance.
What is Biostem Tech's revenue over the trailing twelve months?
Over the trailing twelve months, Biostem Tech reported a revenue of $210.39M.
What is the EBITDA for Biostem Tech?
Biostem Tech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $20.15M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Biostem Tech?
Biostem Tech has a free cash flow of $14.51M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Biostem Tech's shares?
The free float of Biostem Tech is 11.85M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $235.93M
- EPS (TTM)
- $0.638
- Free Float
- 11.85M
- P/E ratio (TTM)
- 22.65
- Revenue (TTM)
- $210.39M
- EBITDA (TTM)
- $20.15M
- Free Cashflow (TTM)
- $14.51M
Pricing
- 52W span
- $4.41$28.26
Analyst Ratings
Information
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. It offers pre-treatment assessment, cell therapies, anti-aging, and wellness compounds. The company was founded by Andrew Smith Van Vurst, Henry W. Van Vurst IV, and Jason Matuszewski on April 29, 1939 and is headquartered in Pompano Beach, FL.
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US0906842002
- Primary Ticker
- BSEM